SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending ahead of its earnings release as investors weigh the company's massive cash position and improved profitability against frustrations over the lack of a clear acquisition strategy and the company's decision to bypass a traditional conference call. While some shareholders are pushing for a 'No' vote on the CEO's compensation package, the community remains deeply divided between those betting on a long-term 'deep value' transformation and others who feel the stock has become a stagnant play dominated by algorithmic trading and short interest.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is currently trending as traders debate whether it is a high-potential turnaround play leveraging AI-integrated mortgage innovation or a fundamentally challenged firm vulnerable to macroeconomic pressures. The community remains deeply divided, with bulls pointing to aggressive growth and leadership updates while bears focus on geopolitical risks, interest rate pressures, and potential downside price discovery.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing extreme volatility and intense community debate following a reported legislative draft that would ban interest-bearing stablecoin yields, sparking fears that its core reserve-income business model is under threat. While some traders are aggressively shorting the stock on concerns of a permanent loss of competitive edge, others are dismissing the sell-off as an overreaction to "fake news" or algorithmic FUD, maintaining a bullish outlook on the stock's role in the future of digital payments.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently facing significant investor skepticism and volatility as the community reacts to the implementation of a 1-for-12 reverse stock split. Investors are actively debating the company's long-term viability, citing concerns over subscriber retention, a lack of transparent management communication, and fears of further dilution despite the firm's consolidated sports-streaming strategy.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin on the Solana network, igniting polarized community debates between investors betting on explosive, rapid gains and skeptics warning of a classic pump-and-dump scheme. The conversation is dominated by social media promotion and FOMO, with participants actively tracking its liquidity, holder concentration, and potential for volatility.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense trading activity as investors react to its concentrated exposure in high-profile AI startups like Anthropic and OpenAI, with many members debating whether current valuations reflect genuine long-term potential or a speculative bubble driven by a limited float. Discussion is particularly heated regarding the fund's significant premium over its last reported net asset value, with some participants bracing for volatility once share lockups eventually expire.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly is seeing renewed investor interest driven by its expanding role in U.S. defense, particularly through recent contracts to provide FPV drones and training to Air Force Special Operations. The community is actively debating the company's growth trajectory and competitive standing against peers like ONDS and RCAT, with many closely tracking potential military contract news and the firm's overall manufacturing scale-up.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors digest the unexpected pre-release of quarterly earnings alongside a doubled revenue outlook and the acquisition of World View, sparking intense debate over whether the company's aggressive growth strategy justifies its valuation. The community is focused on the upcoming conference call, with many traders looking for further clarity on profitability and potential partnerships to break the stock out of its recent range-bound trading pattern.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently attracting intense community interest as it expands its infrastructure into AI-driven payments through initiatives like AgentKit and the x402 protocol, even as the stock navigates broader volatility and regulatory uncertainty surrounding stablecoin yield legislation. Investors are actively debating the company's long-term competitive position as an "everything exchange" while closely monitoring price action alongside Bitcoin's recent momentum and institutional inflow patterns.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending as investors weigh significant network expansion and institutional RWA adoption against broader market volatility and negative sentiment surrounding altcoin liquidity. While community members are actively debating the timing of a potential price rebound, discussions are heavily centered on recent ecosystem updates and the long-term outlook for utility-focused crypto projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

Equity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Shares of Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, fell nearly 7% on Wednesday, after a series of high-profile stock sales by key executives, prompting bearish sentiment among retail investors.According to recent SEC filings, the company’s CFO, Phillip Juhan, sold $1.92 million worth of shares, while CEO Devin Nunes offloaded shares worth $63,210.&nbsp;Other executives who sold shares include COO Andrew Northwall ($78,700), CTO Vladimir Novachki ($177,082) and General Counsel and Secretary Scott Glabe ($92,684).The filings clarify that these sales were conducted to cover withholding payments to taxing authorities, with no cash proceeds received by the executives.&nbsp;However, the optics of top executives selling shares have rattled investors.On Stocktwits, sentiment for DJT has turned ‘extremely bearish’ (13/100) amid high levels of chatter.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_28_c3c9ff623c.png" alt="DJT sentiment and message volume Aug 28.png">One bearish user (with apparent sarcasm) posted, “$DJT strong support at $0,” while another claimed to have profited $82,000 by shorting the stock.<stembedurl>https://stocktwits.com/theta4life/message/584409755</stembedurl>Additionally, a lock-up period barring former President Donald Trump from selling his shares in the company is nearing its end.&nbsp;According to <a href="https://qz.com/donald-trump-media-stock-holdings-djt-lockup-selloff-1851629076">Quartz</a>, Trump’s stake in DJT is under a six-month lockup period that could end as soon as Sept. 20 — if the stock remains above $12 for any 20 trading days starting Aug. 22. If shares fall below $12, the earliest Trump could sell would be Sept. 25, regardless of the stock’s value.&nbsp;John Rekenthaler, Vice President of Research at Morningstar, reportedly believes DJT is “extremely overvalued” and sees it as a great cash-out opportunity for Trump, who in theory has “well over $2 billion to realize.”DJT’s slide has also been exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenue.&nbsp; Shares of the company, which have been extremely volatile due to news events involving Trump, have lost more than 65% of their value since going public via a SPAC merger in March.<stembedurl>https://stocktwits.com/RonSwanson1/message/584401019</stembedurl>Trump is set to debate Vice President Kamala Harris live on Sept. 10 in Philadelphia. With DJT stock near record lows and a potential Trump stock sale on the horizon, analysts like Rekenthaler warn that a political defeat could push the stock “to zero.”Read Next: <a href="https://stocktwits.com/news/markets/equity/anf-stock-falls-after-q2-results/c7w7XRoR2P">Abercrombie &amp; Fitch Stock Sinks As CEO Points To 'Increasingly Uncertain Environment' — Retail Bulls Aren’t Backing Down</a>&nbsp;&nbsp;&nbsp; &nbsp;

Donald Trump speaking with supporters at a campaign rally at the Phoenix Convention Center in Phoenix, Arizona.

Trump Media & Tech Stock Plummets, Retail Gets ‘Extremely Bearish’ After Key Execs Dump Shares 

A six-month lock-up period barring former President Donald Trump from selling his shares in the company is also nearing its end.

Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, saw its shares fall to a new post-merger low of $21.99 on Tuesday, with retail investor sentiment souring on the stock. &nbsp;According to Stocktwits, sentiment for DJT has turned bearish, falling from ‘neutral’ (36/100) a day earlier.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_20_14dd9018ba.png" alt="DJT sentiment and message volume Aug 20.png" width="1310" height="316"><figcaption>DJT sentiment and message volume Aug 20</figcaption></figure>The stock hit an intraday low of $22.24 on Monday, slipping nearly 1.3% from its previous low seen in mid-April.This downturn follows several weeks of declining stock prices, exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenues.Since its Nasdaq debut in March under the ticker DJT, following a merger with Digital World Acquisition Corp., Trump Media's stock has plunged over 61%, with a nearly 36% drop in the past month alone.Shares of the company have been on a volatile ride this year, primarily driven by <a href="https://stocktwits.com/news/markets/equity/trump-media-stock-retail-sentiment-extremely-bearish-after-biden-exits-2024-race/c7rTFviRv">news events</a> involving former President Donald Trump, the company's majority shareholder.Recent setbacks include the stock slipping after Trump returned to Twitter (now X) for a conversation with Elon Musk, the fallout from Trump’s legal troubles and debate performance against President Joe Biden.There was some limited upside movement following <a href="https://stocktwits.com/news/markets/equity/Trump-stocks-surge-after-shooting-but-retail-traders-divided/c7AZ9lnRT">the assassination attempt</a> on Trump in July during a rally near Butler, Pennsylvania.The stock is facing more pressure as the Democratic National Convention convenes in Chicago on Thursday, when Vice President Kamala Harris will formally accept her nomination for the White House race.<stembedurl>https://stocktwits.com/RickeyBobby/message/583493412</stembedurl>Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic, with some asking the hard questions.&nbsp;<stembedurl>https://stocktwits.com/Mishka1/message/583489536</stembedurl>As the political landscape heats up, DJT’s stock stands on increasingly shaky ground.See Also:&nbsp;<a href="https://stocktwits.com/news/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">Emergent, Geovax, Tonix, Siga: Which Mpox-Linked Stocks Are Retail Investors Most Excited About?</a>

Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic. Photo via Rawpixel

Trump Media Stock Declines To Record Post-Merger Low, Retail Sentiment Sours

The stock, closely tied to former President Trump’s actions and legal issues, has plunged over 61% since going public via a SPAC merger this year.

Current Price	$65.16
Prev Close	$64.86
Open	$64.38
Dividend Yield	N/A
50-Day Moving Average	$67.98
Beta	N/A
Avg. Volume	4,761.13
PE Ratio	N/A

52-Week High	$70.45
52-Week Low	$46.59
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

ISCB
iShares Morningstar Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ISCB News

ISCBiShares Morningstar Small-Cap ETF